3Q23 Revenues Report: Bioton Sees a 12% YoY Decline, Driven by Insulin Sales Drop of 18%FOREXGPW’s Analytical Coverage Support Programme 3.0
2Q23 Financial Performance Review: Steady Revenues, Challenges in Insulin Sales, and Margin AdjustmentsFOREXGPW’s Analytical Coverage Support Programme 3.0
